About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Infectious Disease Diagnostics Market Size, Share, SWOT Analysis and Key Developments
Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market Size, Share & Trends Analysis Report By Applications (Hepatitis, Human Immunodeficiency Virus (HIV), Chlamydia Trachomatis Genital Infection, Gonorrhea (CT/NG), Hospital-Acquired Infections, Human Papillomavirus (HPV), Tuberculosis (TB), Influenza), By Product (Assays, Kits, and Reagents, Instruments, Services and Software), By Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Immunodiagnostics, DNA Microarray, Clinical Microbiology, DNA Sequencing and Next-Generation Sequencing (NGS)) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI3645DR
Last Updated : March 17, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Infectious Disease Diagnostics Market Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. Hepatitis
        1. By Value
      3. Human Immunodeficiency Virus (HIV)
        1. By Value
      4. Chlamydia Trachomatis Genital Infection
        1. By Value
      5. Gonorrhea (CT/NG)
        1. By Value
      6. Hospital-Acquired Infections
        1. By Value
      7. Human Papillomavirus (HPV)
        1. By Value
      8. Tuberculosis (TB)
        1. By Value
      9. Influenza
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Instruments
        1. By Value
      4. Services and Software
        1. By Value
    4. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        1. By Value
      4. Immunodiagnostics
        1. By Value
      5. DNA Microarray
        1. By Value
      6. Clinical Microbiology
        1. By Value
      7. DNA Sequencing and Next-Generation Sequencing (NGS)
        1. By Value
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. Hepatitis
        1. By Value
      3. Human Immunodeficiency Virus (HIV)
        1. By Value
      4. Chlamydia Trachomatis Genital Infection
        1. By Value
      5. Gonorrhea (CT/NG)
        1. By Value
      6. Hospital-Acquired Infections
        1. By Value
      7. Human Papillomavirus (HPV)
        1. By Value
      8. Tuberculosis (TB)
        1. By Value
      9. Influenza
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Instruments
        1. By Value
      4. Services and Software
        1. By Value
    4. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        1. By Value
      4. Immunodiagnostics
        1. By Value
      5. DNA Microarray
        1. By Value
      6. Clinical Microbiology
        1. By Value
      7. DNA Sequencing and Next-Generation Sequencing (NGS)
        1. By Value
    5. U.S.
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. Hepatitis
          1. By Value
        3. Human Immunodeficiency Virus (HIV)
          1. By Value
        4. Chlamydia Trachomatis Genital Infection
          1. By Value
        5. Gonorrhea (CT/NG)
          1. By Value
        6. Hospital-Acquired Infections
          1. By Value
        7. Human Papillomavirus (HPV)
          1. By Value
        8. Tuberculosis (TB)
          1. By Value
        9. Influenza
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Instruments
          1. By Value
        4. Services and Software
          1. By Value
      3. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
          1. By Value
        4. Immunodiagnostics
          1. By Value
        5. DNA Microarray
          1. By Value
        6. Clinical Microbiology
          1. By Value
        7. DNA Sequencing and Next-Generation Sequencing (NGS)
          1. By Value
    6. Canada
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. Hepatitis
        1. By Value
      3. Human Immunodeficiency Virus (HIV)
        1. By Value
      4. Chlamydia Trachomatis Genital Infection
        1. By Value
      5. Gonorrhea (CT/NG)
        1. By Value
      6. Hospital-Acquired Infections
        1. By Value
      7. Human Papillomavirus (HPV)
        1. By Value
      8. Tuberculosis (TB)
        1. By Value
      9. Influenza
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Instruments
        1. By Value
      4. Services and Software
        1. By Value
    4. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        1. By Value
      4. Immunodiagnostics
        1. By Value
      5. DNA Microarray
        1. By Value
      6. Clinical Microbiology
        1. By Value
      7. DNA Sequencing and Next-Generation Sequencing (NGS)
        1. By Value
    5. U.K.
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. Hepatitis
          1. By Value
        3. Human Immunodeficiency Virus (HIV)
          1. By Value
        4. Chlamydia Trachomatis Genital Infection
          1. By Value
        5. Gonorrhea (CT/NG)
          1. By Value
        6. Hospital-Acquired Infections
          1. By Value
        7. Human Papillomavirus (HPV)
          1. By Value
        8. Tuberculosis (TB)
          1. By Value
        9. Influenza
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Instruments
          1. By Value
        4. Services and Software
          1. By Value
      3. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
          1. By Value
        4. Immunodiagnostics
          1. By Value
        5. DNA Microarray
          1. By Value
        6. Clinical Microbiology
          1. By Value
        7. DNA Sequencing and Next-Generation Sequencing (NGS)
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. Hepatitis
        1. By Value
      3. Human Immunodeficiency Virus (HIV)
        1. By Value
      4. Chlamydia Trachomatis Genital Infection
        1. By Value
      5. Gonorrhea (CT/NG)
        1. By Value
      6. Hospital-Acquired Infections
        1. By Value
      7. Human Papillomavirus (HPV)
        1. By Value
      8. Tuberculosis (TB)
        1. By Value
      9. Influenza
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Instruments
        1. By Value
      4. Services and Software
        1. By Value
    4. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        1. By Value
      4. Immunodiagnostics
        1. By Value
      5. DNA Microarray
        1. By Value
      6. Clinical Microbiology
        1. By Value
      7. DNA Sequencing and Next-Generation Sequencing (NGS)
        1. By Value
    5. China
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. Hepatitis
          1. By Value
        3. Human Immunodeficiency Virus (HIV)
          1. By Value
        4. Chlamydia Trachomatis Genital Infection
          1. By Value
        5. Gonorrhea (CT/NG)
          1. By Value
        6. Hospital-Acquired Infections
          1. By Value
        7. Human Papillomavirus (HPV)
          1. By Value
        8. Tuberculosis (TB)
          1. By Value
        9. Influenza
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Instruments
          1. By Value
        4. Services and Software
          1. By Value
      3. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
          1. By Value
        4. Immunodiagnostics
          1. By Value
        5. DNA Microarray
          1. By Value
        6. Clinical Microbiology
          1. By Value
        7. DNA Sequencing and Next-Generation Sequencing (NGS)
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. Hepatitis
        1. By Value
      3. Human Immunodeficiency Virus (HIV)
        1. By Value
      4. Chlamydia Trachomatis Genital Infection
        1. By Value
      5. Gonorrhea (CT/NG)
        1. By Value
      6. Hospital-Acquired Infections
        1. By Value
      7. Human Papillomavirus (HPV)
        1. By Value
      8. Tuberculosis (TB)
        1. By Value
      9. Influenza
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Instruments
        1. By Value
      4. Services and Software
        1. By Value
    4. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        1. By Value
      4. Immunodiagnostics
        1. By Value
      5. DNA Microarray
        1. By Value
      6. Clinical Microbiology
        1. By Value
      7. DNA Sequencing and Next-Generation Sequencing (NGS)
        1. By Value
    5. UAE
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. Hepatitis
          1. By Value
        3. Human Immunodeficiency Virus (HIV)
          1. By Value
        4. Chlamydia Trachomatis Genital Infection
          1. By Value
        5. Gonorrhea (CT/NG)
          1. By Value
        6. Hospital-Acquired Infections
          1. By Value
        7. Human Papillomavirus (HPV)
          1. By Value
        8. Tuberculosis (TB)
          1. By Value
        9. Influenza
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Instruments
          1. By Value
        4. Services and Software
          1. By Value
      3. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
          1. By Value
        4. Immunodiagnostics
          1. By Value
        5. DNA Microarray
          1. By Value
        6. Clinical Microbiology
          1. By Value
        7. DNA Sequencing and Next-Generation Sequencing (NGS)
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Applications
      1. Introduction
        1. Applications By Value
      2. Hepatitis
        1. By Value
      3. Human Immunodeficiency Virus (HIV)
        1. By Value
      4. Chlamydia Trachomatis Genital Infection
        1. By Value
      5. Gonorrhea (CT/NG)
        1. By Value
      6. Hospital-Acquired Infections
        1. By Value
      7. Human Papillomavirus (HPV)
        1. By Value
      8. Tuberculosis (TB)
        1. By Value
      9. Influenza
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Assays, Kits, and Reagents
        1. By Value
      3. Instruments
        1. By Value
      4. Services and Software
        1. By Value
    4. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        1. By Value
      4. Immunodiagnostics
        1. By Value
      5. DNA Microarray
        1. By Value
      6. Clinical Microbiology
        1. By Value
      7. DNA Sequencing and Next-Generation Sequencing (NGS)
        1. By Value
    5. Brazil
      1. By Applications
        1. Introduction
          1. Applications By Value
        2. Hepatitis
          1. By Value
        3. Human Immunodeficiency Virus (HIV)
          1. By Value
        4. Chlamydia Trachomatis Genital Infection
          1. By Value
        5. Gonorrhea (CT/NG)
          1. By Value
        6. Hospital-Acquired Infections
          1. By Value
        7. Human Papillomavirus (HPV)
          1. By Value
        8. Tuberculosis (TB)
          1. By Value
        9. Influenza
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Assays, Kits, and Reagents
          1. By Value
        3. Instruments
          1. By Value
        4. Services and Software
          1. By Value
      3. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Isothermal Nucleic Acid Amplification Technology (INAAT)
          1. By Value
        4. Immunodiagnostics
          1. By Value
        5. DNA Microarray
          1. By Value
        6. Clinical Microbiology
          1. By Value
        7. DNA Sequencing and Next-Generation Sequencing (NGS)
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Infectious Disease Diagnostics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Biomerieux Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Abbott Laboratories
    3. Becton, Dickinson and Company
    4. Bio-Rad Laboratories Inc.
    5. Danaher Corporation
    6. F. Hoffmann-La Roche Ag
    7. Siemens Healthcare Gmbh
    8. Thermo Fisher Scientific Inc
    9. Quidel Corporation
    10. Diasorin Spa (Luminex Corporation)
    11. Trinity Biotech Plc
    12. Quest Diagnostics
    13. Sysmex Corporation
    14. Ortho-Clinical Diagnostics
    15. Seegene Inc
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Market Overview The global autoimmune disease diagnostics market size was valued at USD 4,253.29 million in 2021 and is anticipated to generate 8089.97 million by 2030. The market is projected to grow at a CAGR of 7.17% during the forecast period (2
Buy Now
Global Report
Infectious Disease Testing Market Insights The global infectious disease testing market size was valued at USD 24.2 billion in 2022 and is projected to reach USD 41.5 billion by 2031, growing at a CAGR of 6.2% during the forecast period (2023–
Buy Now
Global Report
Rare Disease Diagnostics Market Size The global rare disease diagnostics market size was valued at USD 1,152.35 million in 2024 and is projected to reach from USD 1,312.86 million in 2025 to USD 3,726.57 million by 2033, growing at a CAGR of 14.30%
Buy Now
Global Report
The global veterinary infectious disease diagnostics market size was valued at USD 1.93 billion in 2022. It is estimated to reach USD 3.95 billion by 2031, growing at a CAGR of 8.49% during the forecast period (2023–2031). Veterinary infectiou
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.